BioMed X launches global ‘Rapid Antiviral Response’ initiative to prepare for future pandemics
The current coronavirus pandemic is teaching us an important lesson: While SARS-CoV-2 is causing unprecedented damage, we need to make sure that this will never happen again.
BioMed X’s Founder and Managing Director wins Business Worldwide Magazine’s CEO Award
The Founder and Managing Director of biotechnology company BioMed X has been named ‘Biotechnology CEO Of The Year – Europe’ in the Business Worldwide Magazine 2020 CEO Awards.
BioMed X starts new schizophrenia research program with Boehringer Ingelheim
The aim of the new research project is to investigate myelination deficits of the adolescent brain in connection with the development of schizophrenia.
We enable our partners to outsource preclinical research in high-risk exploratory fields. Our crowdsourcing platform allows us to identify and recruit the world’s best early-career academic research talents for each project.